Skip to main content
Alligator Bioscience logo

Alligator Bioscience — Investor Relations & Filings

Ticker · ATORX ISIN · SE0024173637 LEI · 549300E15VI0MB7LXV19 ST Manufacturing
Open in API
Filings indexed 610 across all filing types
Latest filing 2019-05-16 Regulatory Filings
Country SE Sweden
Listing ST ATORX

About Alligator Bioscience

https://alligatorbioscience.se/en/

Alligator Bioscience is a clinical-stage biotechnology company that develops tumor-directed immuno-oncology antibody drugs. The company's core strategy is to activate the patient's own immune system to fight cancer. It utilizes a proprietary technology platform for the discovery and development of novel antibody-based pharmaceuticals. The development pipeline features several drug candidates, including its lead asset mitazalimab, a CD40 agonist. The company specializes in creating therapeutics that are designed to be effective against various forms of cancer.

Recent filings

Filing Released Lang Actions
Alligator Bioscience to present the ATOR-1015 Phase I study outline at ASCO
Regulatory Filings Classification · 1% confidence The document is a press release from Alligator Bioscience announcing that an outline of their ATOR-1015 Phase I study will be presented at the ASCO Annual Meeting. It details the study's purpose, design, and presentation specifics. This is not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive interim report (IR). It is an announcement related to clinical trial progress and investor relations, but it does not fit the specific definitions for Investor Presentation (IP) which usually contains strategy/financials, or Management Reports (MDA). Since it is a specific announcement about clinical data presentation, and it is not a general regulatory filing (RNS), the closest fit among the provided options for company updates that aren't formal financial reports or management changes is often categorized under general investor communication. Given the options, and recognizing this is a specific update about a clinical trial presentation, it is best classified as a general announcement that doesn't fit the highly specific financial/regulatory codes. Therefore, the fallback category 'Regulatory Filings' (RNS) is the most appropriate general category for non-standard, non-financial press releases, although 'LTR' (Legal Proceedings Report) is for lawsuits, and 'IP' (Investor Presentation) is usually for the presentation deck itself, not the announcement of the presentation. Given the context of a biotech company announcing clinical data presentation, RNS serves as the best general catch-all for such specific operational news that isn't a core financial report.
2019-05-16 English
Alligator Bioscience: ADC-1013 clinical Phase I data to be presented at ASCO
Regulatory Filings Classification · 1% confidence The document is a press release from Alligator Bioscience announcing that data from a Phase I clinical study of their drug candidate ADC-1013 will be presented at the ASCO Annual meeting. It details preliminary safety, tolerability, and early clinical activity findings. This type of announcement, which communicates specific scientific or operational updates outside of standard mandatory financial reports (like 10-K or ER), fits best under the general 'Regulatory Filings' category (RNS) as it is an official market communication regarding company progress, often mandated by market abuse regulations (as noted in the closing paragraph: 'This information is such information as Alligator Bioscience AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation'). It is not a full report (10-K, IR), an earnings release (ER), or a management discussion (MDA).
2019-05-15 English
Alligator Bioscience: Klinisk fas I-data för ADC-1013 presenteras på ASCO
Regulatory Filings Classification · 1% confidence The document is a press release from Alligator Bioscience dated May 15, 2019, announcing that clinical Phase I data for their drug candidate ADC-1013 will be presented at the ASCO Annual Meeting. It details safety, tolerability, and preliminary efficacy signals from the study. The text concludes with standard boilerplate information, contact details, and a statement regarding EU Market Abuse Regulation disclosure requirements, indicating it is an official company announcement regarding business/research progress. This type of announcement, focusing on clinical trial updates and upcoming presentations, is best classified as a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were the presentation itself. Since it is an announcement *about* data being presented elsewhere, and it doesn't fit the specific definitions for ER, IR, or LTR, RNS (Regulatory Filings/General Announcement) is the most appropriate fallback for this type of corporate news release, especially given the regulatory disclosure statement at the end. It is not a full report (10-K, IR) nor a specific management/board change (MANG, DIRS).
2019-05-15 Swedish
Kommuniké från årsstämma den 9 maj 2019 i Alligator Bioscience AB (publ)
AGM Information Classification · 1% confidence The document is titled "Kommuniké från årsstämma den 9 maj 2019 i Alligator Bioscience AB (publ)" which translates to "Communiqué from the Annual General Meeting (AGM) held on May 9, 2019, in Alligator Bioscience AB (publ)". The text details the decisions made during the meeting, including the approval of financial statements, discharge of the board, election of directors and auditors, and authorization for new share issues. These are all typical components of an AGM summary or minutes. Therefore, the most appropriate classification is AGM Information (AGM-R).
2019-05-09 Swedish
Bulletin from the Annual Shareholders’ Meeting in Alligator Bioscience AB (publ) on May 9, 2019
AGM Information Classification · 1% confidence The document is explicitly titled "Bulletin from the Annual Shareholders' Meeting in Alligator Bioscience AB (publ) on May 9, 2019." It details resolutions passed regarding the adoption of accounts, discharge from liability, election of board members and auditor, remuneration policies, and authorization for new share issues. These topics are central to the proceedings and outcomes of an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM-R (AGM Information). The document is a summary/bulletin of the meeting, not a proxy statement (PSI) or a general regulatory filing (RNS).
2019-05-09 English
The Nomination Committee’s proposal for the annual shareholders’ meeting in Alligator Bioscience AB (publ)
AGM Information Classification · 1% confidence The document explicitly states it is the 'Nomination Committee's proposal for the annual shareholders' meeting' and details proposed elections and remuneration for the board members to be voted upon at the upcoming AGM on May 9, 2019. This content directly relates to the agenda and proposals presented for shareholder approval at an Annual General Meeting (AGM). While it touches upon remuneration (DEF 14A) and board composition (MANG), the primary context is the formal proposal package for the AGM itself. Therefore, AGM-R (AGM Information) is the most appropriate classification.
2019-04-17 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.